Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mid-cap Healthcare Stocks The Smart Money Is Crazy About

Page 1 of 2

With the latest round of 13F filings behind us, there were several moves and trends that caught our attention during the second quarter, based on the collective activity of the smart money we track (the absolute best of the best money managers in the world). Insider Monkey has processed the data relating to these filings and has shared a few of these findings already, through a series of articles. Some of the information that we have covered in our previous pieces include the most popular overall stocks, that stocks that hedge funds were hoarding shares of, and the transportation stocks that hedge funds were selling out of, among others. In this article, we focus on the five mid-cap healthcare stocks that hedge funds are crazy about. To know more about which stocks these are, read on.

Most Prestigious Jobs In America

But why do we track the hedge fund activities? From one point of view we can argue that hedge funds are consistently underperforming when it comes to net returns over the last three years, when compared to the S&P 500. But that doesn’t mean that we should completely neglect the hedge funds’ activities. There are various reasons behind the low hedge fund returns. Our research indicated that hedge funds’ long positions actually beat the market. In our back-tests covering the 1999-2012 period hedge funds’ top small cap stocks edged the S&P 500 index by double digits annually. The 15 most popular small cap stock picks among hedge funds also bested passive index funds by around 60 percentage points over the 35 month period beginning in September 2012, delivering 118% returns (read the details here).

5. DaVita HealthCare Partners Inc (NYSE:DVA)

Investors with Long Positions (as of June 30): 44

Aggregate Value of Investors’ Holdings (as of June 30): $5.29 Billion

During the second quarter, the number of hedge funds tracked by Insider Monkey that were long in DaVita HealthCare Partners Inc (NYSE:DVA) increased by six. On the contrary, the aggregate of hedge funds in the stock dropped by 2.98%. The Denver, Colorado-based kidney care company announced on Monday that it would be acquiring Renal Ventures for $415 million in a bid to boost its kidney division. Renal Ventures was a privately-owned company that provides dialysis care to patients. DaVita HealthCare Partners Inc (NYSE:DVA) is up by 1.2% year-to-date, but has lost 8.82% over the past three months. Berkshire Hathaway, led by legendary investor Warren Buffett, emerged as the biggest shareholder out of the firms we track, with 38.57 million shares worth $3.06 billion. Billionaire Stephen Mandel’s Lone Pine Capital came in a distant second with 5.46 million shares valued at $433.57 million. John Armitage‘s Egerton Capital Limited, Israel Englander’s Millennium Management, and Anand Parekh’s Alyeska Investment Group are some of the funds that upped their positions in DaVita HealthCare Partners Inc (NYSE:DVA) during the quarter.

4. Edwards Lifesciences Corp (NYSE:EW)

Investors with Long Positions (as of June 30): 46

Aggregate Value of Investors’ Holdings (as of June 30): $2.16 Billion

Edwards Lifesciences Corp (NYSE:EW) is another mid-cap healthcare stock that posted an increase in the number of hedge funds with long positions, out of the ones we track, with that figure rising by eight during the second quarter of 2015. Their aggregate holdings were also up by 25.14%. Edwards Lifesciences is a medical equipment company based in Irvine, California, specializing in the design and manufacture of artificial heart valves and devices for hemodynamic monitoring. Edwards Lifesciences Corp (NYSE:EW) recently announced the completion of its acquisition of CardiAQ Valve Technologies, Inc., a company that specializes in the development of transcatheter mitral valve replacement systems. The merger agreement says that Edwards paid $350 million in cash and will part with an additional $50 million upon the achievement of a European regulatory milestone. At the end of the second quarter, AQR Capital Management, led by Cliff Asness, emerged as the biggest shareholder of the company out of the funds we track. The fund held 2.40 million shares worth $342.19 million after raising its stake in the stock by 25%.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!